Device Trial Radar · NCT05883631
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
Last checked: Nov 20, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Oct 23, 2023
Primary completion
Jan 2026
Study completion Jan 2026
Sponsor
- Lead sponsor
- CortexNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Ablacon, Inc.
- First posted
- Jun 1, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Demonstrate the safety and effectiveness of the Ablacath™ Mapping Catheter and Ablamap® System in patients with all types of atrial fibrillation (AF) including paroxysmal or persistent or long-standing persistent, undergoing and De Novo or Redo procedures. Phenotype patients and demonstrate the prognostication power of Electrographic Flow (EGF®) maps among all subjects using 12-month follow-up outcomes following EGF-guided mapping and ablation.
Conditions
- Atrial Fibrillation
- Atrial Fibrillation, Persistent
- Atrial Fibrillation Paroxysmal
- Arrhythmia
- Arrhythmias, Cardiac
- Atrial Flutter
- Atrial Fibrillation, Paroxysmal or Persistent
- Atrial Arrhythmia
- Atrial Tachycardia
Interventions
Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial FibrillationDevice
In addition to standard touch-up of pulmonary vein isolation, subjects receive targeted source ablation guided by Electrographic Flow™ (EGF) mapping. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF-identified sources with activity above the threshold (≥ 25%) are considered significant and targeted with radiofrequency ablation. The procedure concludes when all EGF-identified sources are eliminated, defined as reducing source activity below the threshold.
Electrographic Flow (EGF) mapping (no ablation)Device
In addition to standard pulmonary vein isolation (PVI), subjects receive Electrographic Flow™ (EGF) mapping. PVI may be performed using any commercially available platform/catheter. EGF mapping enables the full spatiotemporal reconstruction of organized atrial electrical wavefront propagation to identify active sources or origins of excitation that may trigger atrial fibrillation (AF). EGF-identified sources with activity above the threshold (≥ 25%) are marked as relevant; however, no EGF-guided ablations are performed during this index procedure. If subjects have AF recurrence after the 90-day blanking period, they may undergo a recurrence procedure and EGF-guided ablation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with 12-month freedom from AF recurrence (with or without AADs)Time frame: From 90 days to 12 months after index procedure
- Number of participants with freedom from a composite of serious adverse events (SAEs) occurring within 7 days from the index procedureTime frame: From index procedure to 7 days after index procedure
- Demonstrate the predictive value of electrographic flow (EGF) phenotyping for ablation outcomeTime frame: 12 months
Locations
24 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
Grandview Medical Center
Birmingham, Alabama
Banner Health
Phoenix, Arizona
21 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.